Molecular staging estimates occult tumor burden in colorectal cancer

Advances in Clinical Chemistry

Volumn 52, Issue C, 2010, Pages 19-39

  Mejia, Alex ^a   Schulz, Stephanie ^a   Hyslop, Terry ^a   Weinberg, David S ^b   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Guanylyl cyclase C; GUCY2C; Lymph nodes; Metastatic disease; Predictive markers; Prognostic markers; Quantitative reverse transcriptase polymerase chain reaction (qRT PCR); Staging

Indexed keywords

ENTEROTOXIN RECEPTOR; GUANYLATE CYCLASE; RECEPTOR; TUMOR MARKER;

BOOK; CANCER STAGING; CLASSIFICATION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANYLATE CYCLASE; HUMANS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77956991846     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)52007-9     Document Type: Book

References (125)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
2. Compton C.C., Greene F.L. The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 2004, 54:295-308.
3. Greene F.L. AJCC Cancer Staging Manual 2002, Springer, New York. sixth ed.
4. Iddings D., Ahmad A., Elashoff D., Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann. Surg. Oncol. 2006, 13:1386-1392.
5. Nicastri D.G., Doucette J.T., Godfrey T.E., Hughes S.J. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J. Mol. Diagn. 2007, 9:563-571.
6. Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med. 2005, 352:476-487.
7. Ries L.A., Wingo P.A., Miller D.S., et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000, 88:2398-2424.
8. Sobrero A., Kerr D., Glimelius B., et al. New directions in the treatment of colorectal cancer: a look to the future. Eur. J. Cancer 2000, 36:559-566.
9. Wolpin B.M., Meyerhardt J.A., Mamon H.J., Mayer R.J. Adjuvant treatment of colorectal cancer. CA Cancer J. Clin. 2007, 57:168-185.
10. Allee P.E., Tepper J.E., Gunderson L.L., Munzenrider J.E. Postoperative radiation therapy for incompletely resected colorectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1989, 17:1171-1176.
11. Dukes C.E., Bussey H.J. The spread of rectal cancer and its effect on prognosis. Br. J. Cancer 1958, 12:309-320.
12. Galandiuk S., Wieand H.S., Moertel C.G., et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg. Gynecol. Obstet. 1992, 174:27-32.
13. Minsky B.D., Mies C., Rich T.A., Recht A., Chaffey J.T. Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J. Clin. Oncol. 1988, 6:119-127.
14. Newland R.C., Chapuis P.H., Pheils M.T., MacPherson J.G. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 1981, 47:1424-1429.
15. Olson R.M., Perencevich N.P., Malcolm A.W., Chaffey J.T., Wilson R.E. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 1980, 45:2969-2974.
16. Phillips R.K., Hittinger R., Blesovsky L., Fry J.S., Fielding L.P. Large bowel cancer: surgical pathology and its relationship to survival. Br. J. Surg. 1984, 71:604-610.
17. Rubio C.A., Emas S., Nylander G. A critical reappraisal of Dukes' classification. Surg. Gynecol. Obstet. 1977, 145:682-684.
18. Sinicrope F.A., Sugarman S.M. Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology 1995, 109:984-993.
19. Willett C.G., Tepper J.E., Cohen A.M., Orlow E., Welch C.E. Failure patterns following curative resection of colonic carcinoma. Ann. Surg. 1984, 200:685-690.
20. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004, 350:2343-2351.
21. Bilchik A.J., Hoon D.S., Saha S., et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann. Surg. 2007, 246:568-575. discussion 575-577.
22. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 1999, 17:1349-1355.
23. Gray R., Barnwell J., et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. Quasar Collaborative Group.
24. Iddings D., Bilchik A. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J. Surg. Oncol. 2007, 96:671-677.
25. Jones S., Chen W.D., Parmigiani G., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. USA 2008, 105:4283-4288.
26. Ratto C., Sofo L., Ippoliti M., et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis. Colon Rectum 1999, 42:143-154. discussion 154-158.
27. Buie W.D., Rothernberger D.A. Surveillance after curative resection of colorectal cancer: individualing follow-up. Gastrointest. Endosc. Clin. N. Am. 1993, 3:691-713.
28. Sloane J.P. Molecules and micrometastases. Lancet 1995, 345:1255-1256.
29. Greenson J.K., Isenhart C.E., Rice R., Mojzisik C., Houchens D., Martin E.W. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994, 73:563-569.
30. Liefers G.J., Cleton-Jansen A.M., van de Velde C.J., et al. Micrometastases and survival in stage II colorectal cancer. N. Engl. J. Med. 1998, 339:223-228.
31. Andre T., Sargent D., Tabernero J., et al. Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol. 2006, 13:887-898.
32. de Gramont A., Tournigand C., Andre T., Larsen A.K., Louvet C. Targeted agents for adjuvant therapy of colon cancer. Semin. Oncol. 2006, 33:S42-S45.
33. de Gramont A., Tournigand C., Andre T., Larsen A.K., Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin. Oncol. 2007, 34:S37-S40.
34. Fuchs C.S., Mayer R.J. Adjuvant chemotherapy for colon and rectal cancer. Semin. Oncol. 1995, 22:472-487.
35. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 1991, 324:709-715.
36. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990, 322:352-358.
37. Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol. 1993, 11:1879-1887.
38. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 2009, 1-7.
39. Sargent D., Sobrero A., Grothey A., et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 2009, 27:872-877.
40. Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 2004, 22:3408-3419.
41. Figueredo A., Charette M.L., Maroun J., Brouwers M.C., Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J. Clin. Oncol. 2004, 22:3395-3407.
42. Winn R., McClure J. The NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2003, 1:5-13.
43. Frick G.S., Pitari G.M., Weinberg D.S., Hyslop T., Schulz S., Waldman S.A. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev. Mol. Diagn. 2005, 5:701-713.
44. Gelmann A., Desnoyers R., Cagir B., Weinberg D., Boman B.M., Waldman S.A. Colorectal cancer staging and adjuvant chemotherapy. Expert Opin. Pharmacother. 2000, 1:737-755.
45. Waldman S.A., Hyslop T., Schulz S., et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 2009, 301:745-752.
46. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27:2091-2096.
47. Cagir B., Gelmann A., Park J., et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann. Intern. Med. 1999, 131:805-812.
48. Almenoff J.S., Williams S.I., Scheving L.A., Judd A.K., Schoolnik G.K. Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol. Microbiol. 1993, 8:865-873.
49. Carrithers S.L., Barber M.T., Biswas S., et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl. Acad. Sci. USA 1996, 93:14827-14832.
50. Carrithers S.L., Parkinson S.J., Goldstein S., Park P., Robertson D.C., Waldman S.A. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 1994, 107:1653-1661.
51. Cohen M.B., Guarino A., Shukla R., Giannella R.A. Age-related differences in receptors for Escherichia coli heat-stable enterotoxin in the small and large intestine of children. Gastroenterology 1988, 94:367-373.
52. Cohen M.B., Moyer M.S., Luttrell M., Giannella R.A. The immature rat small intestine exhibits an increased sensitivity and response to Escherichia coli heat-stable enterotoxin. Pediatr. Res. 1986, 20:555-560.
53. Guarino A., Cohen M., Thompson M., Dharmsathaphorn K., Giannella R. T84 cell receptor binding and guanyl cyclase activation by Escherichia coli heat-stable toxin. Am. J. Physiol. 1987, 253:G775-G780.
54. Guarino A., Cohen M.B., Giannella R.A. Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by Escherichia coli heat-stable enterotoxin. Pediatr. Res. 1987, 21:551-555.
55. Guarino A., Cohen M.B., Overmann G., Thompson M.R., Giannella R.A. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig. Dis. Sci. 1987, 32:1017-1026.
56. Lucas K.A., Pitari G.M., Kazerounian S., et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000, 52:375-414.
57. Rao M.C., Guandalini S., Smith P.L., Field M. Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. Biochim. Biophys. Acta 1980, 632:35-46.
58. Carrithers S.L., Ott C.E., Hill M.J., et al. Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int. 2004, 65:40-53.
59. Field M. Mechanisms of action of cholera and Escherichia coli enterotoxins. Am. J. Clin. Nutr. 1979, 32:189-196.
60. Field M., Graf L.H., Laird W.J., Smith P.L. Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc. Natl. Acad. Sci. USA 1978, 75:2800-2804.
61. Guerrant R.L., Hughes J.M., Chang B., Robertson D.C., Murad F. Activation of intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli: studies of tissue specificity, potential receptors, and intermediates. J. Infect. Dis. 1980, 142:220-228.
62. Hughes J.M., Murad F., Chang B., Guerrant R.L. Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli. Nature 1978, 271:755-756.
63. Kuno T., Kamisaki Y., Waldman S.A., Gariepy J., Schoolnik G., Murad F. Characterization of the receptor for heat-stable enterotoxin from Escherichia coli in rat intestine. J. Biol. Chem. 1986, 261:1470-1476.
64. Schulz S., Green C.K., Yuen P.S., Garbers D.L. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990, 63:941-948.
65. Li P., Lin J.E., Chervoneva I., Schulz S., Waldman S.A., Pitari G.M. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 2007, 171:1847-1858.
66. Li P., Lin J.E., Snook A.E., et al. Colorectal cancer as a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clin. Trans. Sci. 2008, 1:163-167.
67. Li P., Lin J.E., Snook A.E., Schulz S., Pitari G.M., Waldman S.A. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?. Curr. Mol. Pharmacol. 2008, 2:285-292.
68. Li P., Schulz S., Bombonati A., et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007, 133:599-607.
69. Lin E.J., Li P., Snook A.E., Schulz S., Pitari G.M., Waldman S.A. Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol. 2009, 5:509-522.
70. Lin J.E., Li P., Snook A.E., et al. GUCY2C establishes lineage dependence in intestinal tumorigenesis through AKT. Gastroenterology 2010, 138:241-254.
71. Pitari G.M., Baksh R.I., Harris D.M., Li P., Kazerounian S., Waldman S.A. Interruption of homologous desensitization in cyclic guanosine 3', 5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 2005, 65:11129-11135.
72. Pitari G.M., Di Guglielmo M.D., Park J., Schulz S., Waldman S.A. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl. Acad. Sci. USA 2001, 98:7846-7851.
73. Pitari G.M., Li P., Lin J.E., et al. The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol. Ther. 2007, 82:441-447.
74. Pitari G.M., Lin J.E., Shah F.J., et al. Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis 2008, 29:1601-1607.
75. Pitari G.M., Zingman L.V., Hodgson D.M., et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl. Acad. Sci. USA 2003, 100:2695-2699.
76. Shailubhai K., Yu H.H., Karunanandaa K., et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000, 60:5151-5157.
77. Steinbrecher K.A., Wowk S.A., Rudolph J.A., Witte D.P., Cohen M.B. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am. J. Pathol. 2002, 161:2169-2178.
78. Birkenkamp-Demtroder K., Lotte Christensen L., Harder Olesen S., et al. Gene expression in colorectal cancer. Cancer Res. 2002, 62:4352-4363.
79. Cohen M.B., Hawkins J.A., Witte D.P. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab. Invest. 1998, 78:101-108.
80. Notterman D.A., Alon U., Sierk A.J., Levine A.J. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001, 61:3124-3130.
81. Steinbrecher K.A., Tuohy T.M., Heppner Goss K., et al. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem. Biophys. Res. Commun. 2000, 273:225-230.
82. C. Wilson, S. Schulz, T. Hyslop, S.A. Waldman, Silencing of guanylin and uroguanylin expression in colon cancer (2009). Submitted for publication.
83. Lin E.J., Li P., Snook A.E., Schulz S., Pitari G.M., Waldman S.A. Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncology 2009, 5:509-522.
84. Birbe R., Palazzo J.P., Walters R., Weinberg D., Schulz S., Waldman S.A. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 2005, 36:170-179.
85. Fava T.A., Desnoyers R., Schulz S., et al. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol. 2001, 19:3951-3959.
86. Waldman S.A., Barber M., Pearlman J., Park J., George R., Parkinson S.J. Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro. Cancer Epidemiol. Biomarkers Prev. 1998, 7:505-514.
87. Waldman S.A., Cagir B., Rakinic J., et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis. Colon Rectum 1998, 41:310-315.
88. Schulz S., Hyslop T., Haaf J., et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 2006, 12:4545-4552.
89. Witek M.E., Nielsen K., Walters R., et al. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin. Cancer Res. 2005, 11:8549-8556.
90. B. Phillips, C. Ball, D. Sackett, et al., Levels of evidence 2009, Oxford Centre for Evidence-based Medicine, Available at: http://www.cebm.net/index.aspx?o=1025.
91. Chervoneva I., Li Y., Iglewicz B., Waldman S., Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Stat. Med. 2007, 26:5596-5611.
92. Chervoneva I., Hyslop T., Iglewicz B., et al. Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 2006, 348:198-208.
93. Mejia A., Schulz S., Hyslop T., Weinberg D.S., Waldman S.A. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev. Mol. Diagn. 2009, 9:777-785.
94. Moertel C.G., O'Fallon J.R., Go V.L., O'Connell M.J., Thynne G.S. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986, 58:603-610.
95. Punt C.J., Buyse M., Kohne C.H., et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J. Natl. Cancer Inst. 2007, 99:998-1003.
96. Chang G.J., Rodriguez-Bigas M.A., Skibber J.M., Moyer V.A. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J. Natl. Cancer Inst. 2007, 99:433-441.
97. Govindarajan A., Baxter N.N. Lymph node evaluation in early-stage colon cancer. Clin. Colorectal Cancer 2008, 7:240-246.
98. Johnson P.M., Porter G.A., Ricciardi R., Baxter N.N. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J. Clin. Oncol. 2006, 24:3570-3575.
99. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 2003, 21:2912-2919.
100. Swanson R.S., Compton C.C., Stewart A.K., Bland K.I. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann. Surg. Oncol. 2003, 10:65-71.
101. Tsikitis V.L., Larson D.L., Wolff B.G., et al. Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved. J. Am. Coll. Surg. 2009, 208:42-47.
102. Vather R., Sammour T., Kahokehr A., Connolly A.B., Hill A.G. Lymph node evaluation and long-term survival in Stage II and Stage III colon cancer: a national study. Ann. Surg. Oncol. 2009, 16:585-593.
103. Brown H.G., Luckasevic T.M., Medich D.S., Celebrezze J.P., Jones S.M. Efficacy of manual dissection of lymph nodes in colon cancer resections. Mod. Pathol. 2004, 17:402-406.
104. Herrera-Ornelas L., Justiniano J., Castillo N., Petrelli N.J., Stulc J.P., Mittelman A. Metastases in small lymph nodes from colon cancer. Arch. Surg. 1987, 122:1253-1256.
105. Bilimoria K.Y., Bentrem D.J., Nelson H., et al. Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch. Surg. 2008, 143:832-839. discussion 839-840.
106. Hitchcock C.L., Sampsel J., Young D.C., Martin E.W., Arnold M.W. Limitations with light microscopy in the detection of colorectal cancer cells. Dis. Colon Rectum 1999, 42:1046-1052.
107. Nolan T., Hands R.E., Bustin S.A. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 2006, 1:1559-1582.
108. Abati A., Liotta L.A. Looking forward in diagnostic pathology: the molecular superhighway. Cancer 1996, 78:1-3.
109. Krishna R., Herman G., Wagner J.A. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J. 2008, 10:401-409.
110. Lee J.W., Devanarayan V., Barrett Y.C., et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312-328.
111. Lee J.W., Weiner R.S., Sailstad J.M., et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 2005, 22:499-511.
112. Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers 2002, 18:41-46.
113. Wagner J.A. Back to the future: driving innovation in drug development. Clin. Pharmacol. Ther. 2008, 83:199-202.
114. Wagner J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 2008, 48:631-651.
115. Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 2007, 81:104-107.
116. Williams S.A., Slavin D.E., Wagner J.A., Webster C.J. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov. 2006, 5:897-902.
117. Croner R.S., Peters A., Brueckl W.M., et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 2005, 104:395-404.
118. Frigola J., Song J., Stirzaker C., Hinshelwood R.A., Peinado M.A., Clark S.J. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 2006, 38:540-549.
119. Jen J., Kim H., Piantadosi S., et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med. 1994, 331:213-221.
120. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
121. Wang Y., Jatkoe T., Zhang Y., et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 2004, 22:1564-1571.
122. Wilson C., Schulz S., Waldman S. Cancer biomarkers: where medicine, business, and public policy intersect. Biotechnol. Healthcare 2007, Feb: 1-7.
123. Wilson C., Schulz S., Waldman S.A. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin. Pharmacol. Ther. 2007, 81:153-155.
124. Holland C. FDA-Cleared/Approved Molecular Diagnostic Tests 2006, Association for Molecular PathologyBethesda, Maryland.
125. Quality, Regulation and Clinical Utility of Laboratory-Developed Tests 2010, Agency for Healthcare Research and Qulaity (AHRQ).